{"id":568613,"date":"2021-10-12T16:34:01","date_gmt":"2021-10-12T16:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568613"},"modified":"2021-10-12T16:34:01","modified_gmt":"2021-10-12T16:34:01","slug":"chronic-obstructive-pulmonary-disease-market-shows-moderate-growth-in-the-7mm-during-the-study-period-201830","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-obstructive-pulmonary-disease-market-shows-moderate-growth-in-the-7mm-during-the-study-period-201830_568613.html","title":{"rendered":"Chronic Obstructive Pulmonary Disease market shows moderate growth in the 7MM during the study period (2018-30)"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1634011797.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Obstructive Pulmonary Disease market shows moderate growth in the 7MM during the study period (2018-30)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1634011797.png\" alt=\"Chronic Obstructive Pulmonary Disease market shows moderate growth in the 7MM during the study period (2018-30)\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chronic Obstructive Pulmonary Disease Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Increased understanding of the distinct histology has enabled the development of COPD-specific drugs and has begun to reveal the parallels and differences between the two.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/31cedaa2d96f0c0e7ff8e9e1bf217e1e.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Obstructive Pulmonary Disease market report<\/a><\/strong> provides a thorough comprehension of the Chronic Obstructive Pulmonary Disease historical and forecasted epidemiology and the Chronic Obstructive Pulmonary Disease market trends in the 7MM. The Chronic Obstructive Pulmonary Disease report also analyzes the current Chronic Obstructive Pulmonary Disease treatment algorithms, Chronic Obstructive Pulmonary Disease market dynamics, and unmet medical needs.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight estimates, Chronic Obstructive Pulmonary Disease diagnosed prevalence was over <strong>31 million<\/strong> in the 7MM in 2020, with the US accounting for maximum COPD diagnosed prevalence.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU5 countries, <strong>Germany<\/strong> has the highest COPD diagnosed prevalence while <strong>Spain<\/strong> had the lowest in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to DelveInsight COPD epidemiology analysis, <strong>females<\/strong> are more likely to be affected than <strong>males<\/strong>.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Several companies such as <strong>Sanofi, Regeneron Pharmaceuticals, Verona Pharma PLC, Chiesi Farmaceutici S.p.A., AstraZeneca, GlaxoSmithKline, Mereo BioPharma,<\/strong> and others are developing novel therapies to treat COPD.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key COPD therapies in the pipeline include <strong>Itepekimab, Ensifentrine, Dupixent, CHF6001\/Tanimilast, Fasenra, Nucala, Acumapimod,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The growing prevalence of COPD patients in the 7MM has resulted in a growth in COPD market size.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The COPD market size was found to be <strong>USD 12,134 million<\/strong> in the 7MM in 2020, which DelveInsight estimates is expected to grow significantly by 2030.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request for the sample to know more @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-obstructive-pulmonary-disease-copd-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Obstructive Pulmonary Disease Market Research<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Chronic Obstructive Pulmonary Disease is a prevalent, preventable, and treatable condition defined by chronic respiratory symptoms and airflow limitation caused by airway and alveolar abnormalities, which are mainly induced by considerable exposure to noxious particles or gases.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Chronic Obstructive Pulmonary Disease report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease Gender-Specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease Age-Specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases based on Severity of Airflow<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases based on Symptoms and Exacerbation History COPD<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">COPD treatment focuses on symptom relief, such as coughing and breathing difficulties and preventing respiratory infections. The stage of COPD frequently determines treatments. COPD prevention necessitates some lifestyle adjustments. Smoking cessation is an essential component of any COPD treatment plan. Maintenance and reliever medications are used to treat COPD. The maintenance drugs include inhaled <strong>corticosteroids (ICS), long-acting beta-agonists (LABA), fixed-dose combinations of ICS + LABA, tiotropium (TIO), and inhaled ipratropium or fixed-dose combinations of ipratropium + albuterol.<\/strong> Whereas Reliever medications included <strong>short-acting beta-agonist (SABA), oral corticosteroid (OCS), nebulized ipratropium or combination ipratropium&ndash;albuterol, and antibiotics.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Increased awareness of the unique histology has allowed for the development of COPD-specific drugs and has begun to reveal the parallels and distinctions between the two. These factors, along with the anticipated introduction of new therapies such as <strong>Itepekimab, Ensifentrine, Dupixent,<\/strong> and others, are expected to drive the COPD market during the forecast period (2021&ndash;2030).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Itepekimab: Sanofi\/Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ensifentrine: Verona Pharma PLC<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dupixent: Regeneron Pharmaceuticals\/Sanofi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CHF6001\/Tanimilast: Chiesi Farmaceutici S.p.A.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Fasenra: AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nucala: GlaxoSmithKline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acumapimod: Mereo BioPharma<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get more details on the emerging drugs and companies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Obstructive Pulmonary Disease Pipeline Therapies<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Increasing COPD Awareness<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emergence in development of emerging therapies&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Personalized treatments&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Improvement in diagnostic techniques<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Obstructive Pulmonary Disease Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late recognition of COPD<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">High cost of treatment<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Challenges in existing therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patient-related barriers<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period:<\/strong> 2018-30<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>COPD Key Companies:<\/strong> Sanofi, Regeneron Pharmaceuticals, Verona Pharma PLC, Chiesi Farmaceutici S.p.A., AstraZeneca, GlaxoSmithKline, Mereo BioPharma, among others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>COPD Key Pipeline Therapies:<\/strong> Itepekimab, Ensifentrine, Dupixent, CHF6001\/Tanimilast, Fasenra, Nucala, Acumapimod, and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>COPD Market Segmentation:<\/strong> By Geography, By COPD therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis:<\/strong> Comparative and conjoint analysis of COPD emerging therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used:<\/strong> SWOT Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"104\" \/>\n<col width=\"520\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary of Chronic Obstructive Pulmonary Disease<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Events<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Organizations contributing towards Chronic Obstructive Pulmonary Disease<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Key Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD: Potential of Emerging and Current therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Obstructive Pulmonary Disease: Seven Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">COPD Reimbursement and Market Access<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">23.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Pulmonary Infections Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s <strong>&#8220;Chronic Pulmonary Infections &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong> report delivers an in-depth understanding of the Chronic Pulmonary Infections, historical and forecasted epidemiology, as well as the Chronic Pulmonary Infections market trends in the 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-obstructive-pulmonary-disease-market-shows-moderate-growth-in-the-7mm-during-the-study-period-201830\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-obstructive-pulmonary-disease-market-shows-moderate-growth-in-the-7mm-during-the-study-period-201830\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Obstructive Pulmonary Disease Market Increased understanding of the distinct histology has enabled the development of COPD-specific drugs and has begun to reveal the parallels and differences between the two. DelveInsight&rsquo;s Chronic Obstructive Pulmonary Disease market report provides a thorough &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-obstructive-pulmonary-disease-market-shows-moderate-growth-in-the-7mm-during-the-study-period-201830_568613.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-568613","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568613"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568613\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}